Minnow Street Minnow Street
Buy Day today: Neutral (53) Mixed market breadth · no major macro event

Journey Medical Corp (DERM)

Healthcare Drug Manufacturers - Specialty & Generic
6.40 $
-1.2% vs. previous close
Closing price · As of: 31. Jul 2026
🔔 Watch stock

Stock Watch

Stock Watch will tell you what changes at Journey Medical Corp.

Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.

Appears in These Scanners

This stock currently matches 1 of our scanner strategies — each hit links to the scanner.

Risk & Weakness

Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners

Trading Day

Previous Close
6.50$
Open
6.40$
Day High
6.50$
Day Low
6.20$
Volume
47,038shares

Key levels of the most recently completed trading day — not a live quote.

52-Week Range

52-Week Low 52-Week High
4.40 $ 9.30 $
03/30/2026 01/22/2026

Current price 6.40 $ — 41% of the range above the low.

Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.

Basics

Market Cap
0.2$B
Shares Outstanding
22Mio.
Float
69.2%
Beta
1.1

Performance

Perf. 1M
9.50%
Perf. 3M
48.40%
Perf. 6M
-16.50%
YTD Performance (%)
-13.10%
52-Week-High Distance
-34.9%
Perf. 1Y
-13.33%
Perf. 3Y
230.05%
Perf. 5Y
-30.81%
Perf. Since Inception
-35.66%

Technical Indicators

MA 38 Days
6.60$
MA 50 Days
6.50$
MA 200 Days
7.10$
RSI (14)
45.0
Volatility 30 Days
63.7%
Volatility 250 Days
68.2%

Calculated from the price history · as of 08/03/2026

Valuation

P/E
Forward P/E
212.8
PEG
P/B
P/S
2.6
EV/EBITDA
17.7
Price/FCF

Profitability

Gross Margin
65.4%
EBIT Margin
Net Margin
-14.8%
Return on Equity
-36.6%
Return on Assets
-4.5%

Balance Sheet & Safety

Equity Ratio
Debt/Equity
Altman Z″
1.71
very solid
Piotroski
8 out of 9

Growth

Sales Growth Last Quarter
21.50%
EPS Growth Last Quarter
0.00%
Sales Growth (Year)
10.20%
Forward Sales Growth
66.70%
Forward EPS Growth

Dividend

This stock currently pays no dividend.

Quality & Screener

Stage
4
RS Rating
28
EPS Rating
42
very solid
Piotroski
8 out of 9
Fundamental Rating
D (39 out of 100)
Altman Z″
1.71

AI Rating

Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built

Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.

Analysts & Price Target

Current Price 6.40 $
Price Target (average) 13.50 $

The price target sits 110.9% above the current price.

Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.

Next Reporting Date

11. Aug 2026 · after the close · Q2 2026
Expected Earnings per Share
-0.01 $

Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.

Revenue & Profit

Cash Flow

Balance Sheet

Margins

Per Share

Click the chart or tab into it, then use ← and → to step through the periods.

None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.

These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.

The figures could not be loaded right now.

Sales Per Quarter ($M)
2024: Q4 · 13.6 $M Q4 2025: Q1 · 13.1 $M Q1 2025: Q2 · 15.0 $M Q2 2025: Q3 · 17.6 $M Q3 2025: Q4 · 16.1 $M Q4 2026: Q1 · 16.0 $M Q1

Source: fundamental data

Compare with other stocks →

Quarterly Figures

Quarterly Figures
Quarter EPS (Earnings Per Share) EPS YoY (%) Sales ($M) Sales YoY (%) Net Margin (%) OCF ($M) FCF ($M)
2024: Q4 0.07 14 -10.70 11.20 2 2
2025: Q1 -0.19 13 0.80 -31.00 -3 -3
2025: Q2 -0.18 15 1.00 -25.30 -1 -1
2025: Q3 -0.11 18 20.50 -13.10 -2 -2
2025: Q4 -0.06 -182.00 16 18.10 -7.80 -6 -6
2026: Q1 -0.10 16 21.50 -14.00 3 3
What Do These Terms Mean?
EPS (Earnings Per Share):
Quarterly profit divided by the total share count — how much of the profit works out to a single share.
YoY (Year over Year):
Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
Sales:
All revenue for the quarter, before any costs are deducted — the top line of the income statement.
Net Margin:
What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
OCF (Operating Cash Flow):
The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
FCF (Free Cash Flow):
Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.

About the Company

Journey Medical Corporation, ein Pharmaunternehmen in der Vermarktungsphase, konzentriert sich auf die Entwicklung und Vermarktung pharmazeutischer Produkte zur Behandlung dermatologischer Erkrankungen in den USA. Zu den vermarkteten Produkten gehört Qbrexza, ein medizinisch wirkstoffhaltiges Tuch…

Employees58
HeadquartersScottsdale, AZ
Websitejourneymedicalcorp.com
IPO Date12. Nov 2021

Management

Management
Name Title Birth Year
Lindsay Allan Rosenwald M.D. Executive Chairman 1955
Claude Maraoui Founder, President, CEO & Director 1967
Joseph M. Benesch CFO & Corporate Controller 1967
Ramsey Alloush COO, General Counsel & Company Secretary 1986
Robert Nevin Chief Commercial Officer 1969
Jaclyn Jaffe Senior Director of Corporate Operations
Louis Donati Director of Market Access

Executives per the latest required filings; titles kept in their original language. Source: fundamental data.

Chart

Interactive price chart (TradingView).

Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?